

DLO to Host Speaker Dinner: *Advanced Insights into Residual Cardiovascular Risk*

With more than 50% of heart attack patients having optimal cholesterol levels, it is clear that a more in-depth look at a patient's risk of a heart attack and other heart disorders is needed. Join us for an evening to learn more about advanced lipid testing and how it could improve your patients' outcomes.

On March 13, 2014 at 6:00pm, DLO will host "Advanced Insights into Residual Cardiovascular Risk" at Mickey Mantle's Steakhouse in Oklahoma City. Dr. Carlos Sobral will discuss advanced cardiovascular testing used to identify residual risk of cardiovascular disease through emerging biomarkers. Dr. Sobral's interest over the past 16 years in the interrelationships between cholesterol, diabetes and hypertension stemmed initially from a deep family history of heart attacks, strokes and diabetes. His overriding desire to get his patients to understand how they can prevent these problems drove him to begin treating patients more aggressively -- ten years ago Dr. Sobral began doing advanced lipid testing on his patients. He has seen a significant improvement in patient compliance through the understanding now of more beyond what a standard lipid panel indicates.

If you are interested in attending, please **RSVP before March 6, 2014** by emailing marcia.s.shields@questdiagnostics.com, calling 405.608.6231 or contacting your sales representative.



Dr. Sobral is board certified in family medicine and has practiced for the past 36 years in southern California where he also earned his medical degree. In addition, he studied medicine at the Universidad Autonoma de Guadalajara in Guadalajara, Mexico. Dr. Strobal is a Lecture Bureau speaker for Abbott, Astra Zeneca and Quest Diagnostics, specializing in advanced lipid testing and diabetes.

Get the most up-to-date lab and database changes *instantly and conveniently*

We are excited to announce the March 1 availability of IntelliTest Manager™ which *will replace* the current Laboratory and Database updates on our Website. IntelliTest Manager™ will provide timely information on test changes and new tests available from DLO. Through our flexible web portal, you will have access to Laboratory Update information 24 hours per day, 7 days per week. Through the enhanced filtering and search functions you can identify the information you need to review and export it for later use. You will still have access to the entire list of communications and test changes, current as well as historical, but there is now the option to search for only the information needed.

Visit dolab.com for more information on IntelliTest Manager™.

Features of IntelliTest Manager™

- View test code change documents on-line, 24/7 from any computer with internet access
- Filter the test changes based on your account utilization
- Export pertinent information to various formats
- Filter and/or sort information based on the following criteria: new tests, CPT code, specimen stability, reference range or methodology changes
- View New Test Highlights, which provides clinical usage information on new tests

For more information, call 800.891.2917

Health Trends

Quest: World's Leading Provider of Cancer Diagnostics

DLO offers the most comprehensive capabilities in anatomic pathology and molecular diagnostics through Quest Diagnostics, the world's leading provider of cancer diagnostics. Our innovative test menu includes various options for screening, diagnosis, treatment, and monitoring recurrence.

Our comprehensive test menu extends across the full continuum of care, from predisposition through monitoring. We can help meet your cancer testing needs with our extensive immunohistochemical (IHC) capabilities, comprehensive roster of more than 200 antibodies and extensive flow cytometry capabilities. We are the "go-to" source for the latest molecular testing insights.

Medical and scientific expertise

Quest has approximately 900 MDs and PhDs on staff. Our talented pathologists are available for professional consultations and have expertise spanning a broad range of tumor types and subspecialties:

- 36 board-certified geneticists, 29 are Fellows of the American Board of Clinical Geneticists
- Highly qualified personnel with extensive experience in karyotyping, FISH and CGH

- 60+ board-certified hematopathologists
- Numerous highly experienced surgical pathologists and dermatopathologists

Cancer diagnostics services:

- Enhanced anatomic pathology
- Liquid-based cervical cytology
- Full range of FISH (Fluorescence In Situ Hybridization) testing for solid tumors (paraffin sections)

- Advanced dermatopathology services with over 20,000 melanomas diagnosed annually
- Comprehensive reports with images
- Specialized, complex clinical pathology
- Cytogenetics and FISH for myeloma, lymphomas, myeloproliferative disorders and more

Innovative cancer testing

With four decades of pioneering insights and innovations in cancer diagnostics, we're proud of our tradition, but we are always looking to the future. From ongoing discovery to delivery of new laboratory assays that help detect predisposition or disease and help guide therapeutic decisions, we are focused on advancing laboratory medicine to help improve early detection and cancer care. We collaborate with key academic and biotechnology researchers to bring the benefit of cutting-edge research and development to you. Many of our innovative tests are designed to help promote patient compliance and to minimize discomfort, tests such as:

- OVA1[®], the first FDA-cleared blood test to help assess the likelihood that an ovarian mass is malignant before surgery
- ColoVantage[®], a convenient DNA blood test that aids in the detection of colorectal cancer in patients non-adherent to current testing modalities
- BRCAVantage[™] is a comprehensive offering of genetic tests for the BRCA1 and BRCA2 genes
- Pap, HPV and HPV Genotype testing for cervical cancer
- Gene-based testing
- ClariSure[®] CGH (comparative genomic hybridization) microarrays
- Pharmacogenomics
- Protein testing, including tumor markers

Viral Hepatitis Updates from Center of Disease Control

Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: U.S. Preventive Services Task Force DRAFT Recommendation Statement

The U.S. Preventive Services Task Force recently posted a draft Evidence Report and draft Recommendation Statement on screening for hepatitis B virus infection in nonpregnant adolescents and adults. Both are available for review and public comment through March 10, 2014. To review the draft Evidence Report and draft Recommendation Statement and submit comments, go to <http://www.uspreventiveservicestaskforce.org/tfcomment.htm>.

Test Spotlight

QuestAssureD™ Replaces DLO/Quest Vitamin D Test

Please be reminded that the new name of our [17306 Vitamin D test](#) is [QuestAssureD](#). For those clients using Care360, you should have received a broadcast message alerting you to the name change.

About Vitamin D Testing:

- Improve Practice Economics – Vitamin D deficiency is associated with 7% to 17% of annual healthcare costs. We provide an exquisite test to detect vitamin D deficiency, giving physicians the information to provide an appropriate treatment plan.
- Improve Patient Outcomes – QuestAssureD filters out clinically-irrelevant molecules, so your patients get only the most accurate results.
- Enhance Patient Experience – Accurate testing of vitamin D is imperative to help maintain optimal patient health.

QuestAssureD™ for Infants: Addressing the Needs of a Special Population at Risk for Vitamin D Deficiency

DLO is now offering through Quest Diagnostics an important addition to the family of vitamin D testing: [QuestAssureD for Infants, Test Code 91935](#).

What Is Special About This Test?

Infants have immature endocrine systems, particularly those 0-2 years of age, and can have high levels of a vitamin D component (isomer) circulating in their systems called c3-epimer. While the physiological role of c3-epimer is unknown, we do know that high levels of the isomer can cause falsely elevated levels of vitamin D if not identified and subtracted from a diagnostic test result.

Misclassifying an infant as “sufficient” could prevent appropriate vitamin D supplementation from being prescribed.

Consequences of inadequate vitamin D in infants and during childhood can include growth delay, skeletal deformities (including rickets) and may result in higher risk for hip fracture later in life.

Infants particularly at-risk for vitamin D insufficiency or deficiency include:

- Infants exclusively breast-fed who do not receive vitamin supplementation
- Those who are not exposed to the sun
- Those with fat malabsorption issues such as cystic fibrosis or Celiac disease
- Infants of African American or Hispanic descent
- Those taking certain medications such as anticonvulsants or HIV/AIDS drugs

Quest Diagnostics recognized this need for highly accurate testing of patients 0-2 years of age, and now provides a test using our robust LC/MS/MS method that includes an extra extraction step to subtract c3-epimer from the final result. (Note: we do not report out the c3-epimer level.)

About Vitamin D Testing for Infants:

- Improve Patient Outcomes – Infants who may be missing vitamin D treatment can now be detected and begin a healthier path, long term
- Build a Better Office – Distinguish your office by offering the most current and exquisitely accurate assay for vitamin D detection for infants
- Enhance Patient Experience – Allow parents to have the utmost confidence in your practice through the most state-of-the-art test offerings in the industry



Education Center

Online Education Presentations Now Available



HIV Care 2013: The Role of the Primary Care Provider

Paul E. Sax, MD discusses screening for HIV in the primary care setting, best practices related to the management of patients with HIV infection by primary care physicians, and appropriate strategies for co-management with infectious disease specialists.

<http://www.education.questdiagnostics.com/presentations>

Free CME Webinar



Personalized Cardiac Risk Evaluation: A Focus on Genetics

H. Robert Superko, MD, discusses how genetics can help clinicians better assess the risk of cardiovascular diseases in various individual patients as well as how lab testing can help improve the efficacy of omega-3 fish oil supplementation for the prevention of cardiac events. Includes several cases.

<http://education.questdiagnostics.com/presentations>

Free CME Webinar

Fighting the Urgent Clostridium difficile Threat - Epidemiology, Diagnosis and Management

Neil Stollman, MD, will provide critical information to medical professionals about the transmission, patient impact, testing methods and current practices for C. diff infections, which the CDC describes here as "at an all-time high".

<http://education.questdiagnostics.com/presentations>

Free Webinar - Wednesday, March 5 at 11:00am

Winter 2014

The DLO Newsletter

Empowering
Better Health
with Diagnostic Insights

Presort Std
US Postage
PAID
Okla City, OK
Permit #2186

DIAGNOSTIC
LABORATORY
OF OKLAHOMA



225 NE 97th St.
Oklahoma City, OK 73114